Protective Effect of Valsartan on Beleomycine-Induced Fibrosis

Abstract

Background: Pulmonary fibrosis (PF) is among the world’s most prevalent and common respiratory system diseases. Several previous studies have revealed the contribution of angiotensin in the pathogenesis of PF; subsequently, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor antagonists (ARDs) have been proposed for the treatment of pulmonary fibrosis using therapeutic approaches. Objectives: This study aimed to investigate the anti-fibrotic effect of valsartan as an angiotensin receptor blocker. Methods: Rats were given a single intratracheal administration of bleomycin (7.5 IU/kg); valsartan (20, 40, 80 mg/kg/day) was administrated to the rats orally, starting seven days before the induction of lung fibrosis and continuing until the end of the study. The control group received a vehicle. Results: The rats that received valsartan exhibited decreased hydroxyprolin content and pulmonary index values. Pathological examination showed that valsartan could prevent inflammation and fibrotic scarring induced by bleomycin. Conclusions: Valsartan displayed an anti-fibrotic and protective effect against bleomycin-induced lung fibrosis in an animal model.